StreetInsider.com News Articles

Form 4 NovaBridge Biosciences For: Sep 09 Filed by: Cao Sean Wuxiong

Fri, 11 Sep 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260911/27053229.html

Form 3 NovaBridge Biosciences For: Sep 08 Filed by: Dewhurst Martin William

Thu, 10 Sep 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260910/27048742.html

NovaBridge Biosciences to Participate in September Investor Conferences

Thu, 27 Aug 2026 07:00:00 -0400

ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026:

Conference details:

Cantor 2026 Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Thursday, September 10, 2026
Time: 1:00 PM ET
Webcast Link: Here

H.C. Wainwright 28th Annual Global Investment

NovaBridge Biosciences to Participate in September Investor Conferences

Thu, 27 Aug 2026 07:00:00 -0400

ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026:

Conference details:

Cantor 2026 Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Thursday, September 10, 2026
Time: 1:00 PM ET
Webcast Link: Here

H.C. Wainwright 28th Annual Global Investment

NovaBridge Biosciences to Participate in September Investor Conferences

Thu, 27 Aug 2026 07:00:00 -0400

ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026:

Conference details:

Cantor 2026 Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Thursday, September 10, 2026
Time: 1:00 PM ET
Webcast Link: Here

H.C. Wainwright 28th Annual Global Investment

NovaBridge Biosciences to Participate in September Investor Conferences

Thu, 27 Aug 2026 07:00:00 -0400

ROCKVILLE, Md., Aug. 27, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that the Company’s leadership will participate in the following investor conferences in September 2026:

Conference details:

Cantor 2026 Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Presenter: Srishti Gupta, MD, MPP, Chief Executive Officer, NovaBridge Biosciences
Date: Thursday, September 10, 2026
Time: 1:00 PM ET
Webcast Link: Here

H.C. Wainwright 28th Annual Global Investment

Form 4 NovaBridge Biosciences For: Aug 22 Filed by: Lenz Robert A.

Tue, 25 Aug 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260825/26974934.html

Form 4 NovaBridge Biosciences For: Aug 22 Filed by: Lenz Robert A.

Tue, 25 Aug 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20260825/26974934.html

H.C. Wainwright Reiterates Buy Rating on NovaBridge Biosciences (NBP)

Fri, 21 Aug 2026 06:58:57 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $9.00 price target on NovaBridge Biosciences (NASDAQ: NBP).
The analyst commented: "A key crux of the NovaBridge story that we believe investors still underappreciate is that the company retains meaningful optionality, both in how far it elects to develop givastomig internally and in its ability to identify and advance additional differentiated assets. Nearly 10 months after a global restructuring, the first half of 2026 was defined by notable clinical and regulatory progress across its lead programs. Givastomig, a potential best-in-class bispecific CLDN18.2 x 4-1BB antibody, received confirmation of potential eligibility for

NovaBridge Biosciences (NBP) PT Lowered to $110 at Morgan Stanley

Thu, 20 Aug 2026 08:51:07 -0400
Morgan Stanley lowered its price target on NovaBridge Biosciences (NASDAQ: NBP) to $110.00 (from $115.00) while maintaining a Overweight rating.

Form 6-K NovaBridge Biosciences For: Jun 30

Thu, 20 Aug 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260820/26952650.html

Form 6-K NovaBridge Biosciences For: Jun 30

Thu, 20 Aug 2026 07:01:00 -0400
si-local-file:///var/storage/secattach/20260820/26952650.html

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Thu, 20 Aug 2026 07:00:00 -0400

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders
Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company
Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval Pathway
Progressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durability
Maintained a strong balance sheet with $215.9 million in cash, cash equivalents,

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Thu, 20 Aug 2026 07:00:00 -0400

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders
Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company
Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval Pathway
Progressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durability
Maintained a strong balance sheet with $215.9 million in cash, cash equivalents,

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Thu, 20 Aug 2026 07:00:00 -0400

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders
Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company
Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval Pathway
Progressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durability
Maintained a strong balance sheet with $215.9 million in cash, cash equivalents,

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Thu, 20 Aug 2026 07:00:00 -0400

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders
Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company
Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval Pathway
Progressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durability
Maintained a strong balance sheet with $215.9 million in cash, cash equivalents,

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Thu, 20 Aug 2026 07:00:00 -0400

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders
Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company
Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval Pathway
Progressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durability
Maintained a strong balance sheet with $215.9 million in cash, cash equivalents,

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Thu, 20 Aug 2026 07:00:00 -0400

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders
Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company
Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval Pathway
Progressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durability
Maintained a strong balance sheet with $215.9 million in cash, cash equivalents,

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Thu, 20 Aug 2026 07:00:00 -0400

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders
Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company
Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval Pathway
Progressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durability
Maintained a strong balance sheet with $215.9 million in cash, cash equivalents,

NovaBridge Reports First Half 2026 Financial Results and Highlights Pipeline Momentum and Strategic Execution

Thu, 20 Aug 2026 07:00:00 -0400

Executing NovaBridge’s strategy to identify differentiated science, develop it efficiently and create long-term value for patients and shareholders
Appointed Srishti Gupta, MD, MPP, as Chief Executive Officer, to strengthen strategic oversight, governance, and capital allocation across the Company
Advancing givastomig toward initiating a registrational Phase 3 study as early as YE 2026, under a potential Accelerated Approval Pathway
Progressing VIS-101 toward Phase 2b initiation in 2H 2026, following positive Phase 2a results supporting potential best-in-class durability
Maintained a strong balance sheet with $215.9 million in cash, cash equivalents,

Form 6-K NovaBridge Biosciences For: Aug 20

Thu, 20 Aug 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260820/26952631.html

Form 6-K NovaBridge Biosciences For: Aug 20

Thu, 20 Aug 2026 07:00:00 -0400
si-local-file:///var/storage/secattach/20260820/26952631.html

Form S-8 NovaBridge Biosciences

Mon, 17 Aug 2026 06:16:00 -0400
si-local-file:///var/storage/secattach/20260817/26934422.html

Form S-8 NovaBridge Biosciences

Mon, 17 Aug 2026 06:16:00 -0400
si-local-file:///var/storage/secattach/20260817/26934422.html

NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026

Thu, 13 Aug 2026 17:00:00 -0400

ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined development, financing, and partnering strategies to create value, today announced that it will hold a webcast on Thursday, August 20, 2026 at 9:00 AM ET/9:00 PM China Standard Time to discuss recent corporate progress and financial results for the first half ended June 30, 2026.

Webcast Information:

Date: Thursday, August 20, 2026
Time: 9:00 AM ET/9:00 PM China Standard Time